Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Biomarkers, Tumor
  • Breast Neoplasms
  • Paclitaxel
  • Receptor, ErbB-2
  • Stroke Volume
  • Trastuzumab
  • Ventricular Dysfunction, Left
  • Ventricular Function, Left

abstract

  • Cardiac toxic effects from paclitaxel with trastuzumab, manifesting as grade 3 or 4 LVSD or asymptomatic LVEF decline, were low. Patient LVEF was assessed at baseline, 12 weeks, 6 months, and 1 year, and our findings suggest that LVEF monitoring during trastuzumab therapy without anthracyclines could be simplified for many individuals.

publication date

  • January 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5654518

Digital Object Identifier (DOI)

  • 10.1001/jamaoncol.2015.3709

PubMed ID

  • 26539793

Additional Document Info

start page

  • 29

end page

  • 36

volume

  • 2

number

  • 1